Results of a phase II study investigating acalabrutinib for patients with relapsed CLL who can not tolerate ibrutinib therapy.
Home / Resource Library / Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib